Siemens Healthineers Shares Slide After Varian Disappoints
By Cecilia Butini
Shares of Siemens Healthineers dropped in early trading on Wednesday after the company posted disappointing results in its Varian radiation oncology business, according to analysts.
At 0937 GMT, shares traded 7% lower at EUR48.63.
The German health-care company reported higher net profit in its fiscal third quarter, mainly thanks to lower taxes and higher revenue. Growth in the imaging and advanced-therapies segments was broadly offset by a drop in diagnostics sales due to weaker demand for Covid-19 antigen tests, the company said.
Although revenue growth was in line with consensus and Citi estimates, adjusted earnings before interest and taxes came in below consensus, analysts at the bank say in a note, pointing out that the miss was driven exclusively by Varian, which is hit by temporary logistics issues.
The miss at Varian is likely to renew the debate on the margin progression within the business, according to Citi analysts.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
August 02, 2023 06:08 ET (10:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?